DFTX Share Price Performance
US$20.68
15.25 (280.85%)
41.3% undervalued intrinsic discount
US$35.23
Fair Value
Price US$20.68
AnalystConsensusTarget US$35.23
AnalystLowTarget US$20.00
AnalystHighTarget US$63.18
Fair ValueUS$35.23
Share Pricen/a
Definium Therapeutics, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 77 Fair Values set on narratives written by author
DFTX Community Narratives
AN
Fair Value US$35.23 41.3% undervalued intrinsic discount
Pivotal Phase III Readouts And Breakthrough Status Will Redefine Psychedelic Psychiatry Potential
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
Fair Value US$20 3.4% overvalued intrinsic discount
Psychedelic Trial Setbacks And Costly REMS Model Will Test This Long Term Opportunity
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value US$63.18 67.3% undervalued intrinsic discount
Phase III Psychedelic Readouts And Breakthrough Status Will Reshape Anxiety And Depression Treatment
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Phase III Psychedelic Readouts And Breakthrough Status Will Reshape Anxiety And Depression Treatment
Catalysts About Definium Therapeutics Definium Therapeutics is a biopharmaceutical company focused on developing psychedelics-based medicines for generalized anxiety disorder, major depressive disorder and autism spectrum disorder. What are the underlying business or industry changes driving this perspective?Read more
2
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$63.18
67.3% undervalued intrinsic discount
Fair Value
Profit Margin
55.28%
Future PE
18.52x
Price in 2029
US$0
Pivotal Phase III Readouts And Breakthrough Status Will Redefine Psychedelic Psychiatry Potential
Catalysts About Definium Therapeutics Definium Therapeutics develops late stage psychedelic based therapies targeting psychiatric and neurodevelopmental disorders. What are the underlying business or industry changes driving this perspective?Read more
114
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
US$35.23
41.3% undervalued intrinsic discount
Fair Value
Profit Margin
20.06%
Future PE
126.88x
Price in 2029
US$0
Psychedelic Trial Setbacks And Costly REMS Model Will Test This Long Term Opportunity
Catalysts About Definium Therapeutics Definium Therapeutics is a biopharmaceutical company focused on developing psychedelic based treatments for generalized anxiety disorder, major depressive disorder and autism spectrum disorder. What are the underlying business or industry changes driving this perspective?Read more
40
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$20
3.4% overvalued intrinsic discount
Fair Value
Profit Margin
21.47%
Future PE
871.18x
Price in 2029
US$0
Trending Discussion
Recently Updated Narratives
AN
Phase III Psychedelic Readouts And Breakthrough Status Will Reshape Anxiety And Depression Treatment
Fair Value: US$63.18 67.3% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Pivotal Phase III Readouts And Breakthrough Status Will Redefine Psychedelic Psychiatry Potential
Fair Value: US$35.23 41.3% undervalued intrinsic discount
3 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Psychedelic Trial Setbacks And Costly REMS Model Will Test This Long Term Opportunity
Fair Value: US$20 3.4% overvalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Definium Therapeutics, Inc. Key Details
About DFTX
- Founded
- n/a
- Employees
- 106
- CEO
- WebsiteView website
Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company’s lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Definium Therapeutics, Inc. in January 2026. Definium Therapeutics, Inc. is headquartered in New York, New York.
Recent DFTX News & Updates
